Histamine H4 receptor is a potential target for COVID-19 treatment
Seyed Reza Mirmazloomi, Nazanin Gholinia, Amir Peymani · Electronic physician · 2020
Histamine H4 receptor is a potential target for COVID-19 treatment is a article published in Electronic physician by Seyed Reza Mirmazloomi, Nazanin Gholinia, Amir Peymani on 2020.
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Electronic physician · Electronic Physician · article · 2020
Abstract
Pulmonary fibrosis and cytokine storms are two major complications in COVID-19 patients that can decrease life quality after recovery and even cause death.Histamine H4 Receptor (H4R) antagonists prevent lung fibrosis and reduce TNF-α and IL-6 secretion in several immune-mediated diseases.T-helper cell 17 (TH17), which is an important inflammatory effector in COVID-19 pathogenesis, expresses H4Rs on its surface.The stimulation of these receptors results in IL-17 production and, subsequently, TNF-α and IL-6 secretion, tissue remodelling, and fibrosis.The compatibility of the clinical manifestations of COVID-19 with the H4R function pattern further supports this theory.According to the above content, Histamine 4 receptors could be a potential target for COVID-19 treatment.H4R antagonists should be evaluated in experimental in-vitro studies and randomized controlled trials in terms of their therapeutic and preventive effects in COVID-19 complications, severity progression, and mortality.
Open the resolved locator · 10.19082/7776
Metadata licence: OpenAlex metadata (CC0)